Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 5Prostatic Neoplasms 2Ovarian Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Sarcoma 1Pancreatic Neoplasms 1Melanoma 1Hemangiosarcoma 1Fibrolamellar hepatocellular carcinoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Doxorubicin 5Ifosfamide 4Filgrastim 3belinostat 2Radiotherapy 2Nivolumab 2Ipilimumab 2Imatinib Mesylate 2spartalizumab 1perifosine 1brostallicin 1balstilimab 1Vincristine 1Trabectedin 1Temozolomide 1Sunitinib 1Specimen Handling 1Peripheral Blood Stem Cell Transplantation 1Mass Spectrometry 1Magnetic Resonance Spectroscopy 1Injections 1Fluorouracil 1Etoposide 1Epirubicin 1Dactinomycin 1Cyproheptadine 1Cyclophosphamide 1Chromatography, High Pressure Liquid 1Chemotherapy, Adjuvant 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hemangiosarcoma × balstilimab × Gynecologic × Clear all
NCT03860272 2026-03-30

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Agenus Inc.

Phase 1 Active not recruiting
499 enrolled
GastrointestinalGenitourinaryGynecologicSarcomaThoracic

Fibrolamellar hepatocellular carcinoma, Carcinoma, Non-Small-Cell Lung, Hemangiosarcoma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡